- Home
- ELTX vs HDRN Comparison
ELTX vs HDRN Comparison
Compare ELTX & HDRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELTX | HDRN |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 193.8M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ELTX | HDRN |
|---|---|---|
| Price | $2.89 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 992.3K | 63.1K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.66 | $1.54 |
| 52 Week High | $16.00 | $2.63 |
Technical Indicators
Market Signals| Indicator | ELTX | HDRN |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 25.13 |
| Support Level | $2.72 | N/A |
| Resistance Level | $5.38 | $2.07 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | 0.22 | -0.03 |
| Stochastic Oscillator | 3.95 | 11.21 |
Price Performance
Historical ComparisonAbout ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.